# Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia

> **NCT00028847** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Commissie Voor Klinisch Toegepast Onderzoek** · enrollment: 60 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** cytarabine
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00028847
- **Lead sponsor:** Commissie Voor Klinisch Toegepast Onderzoek
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028847, "Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00028847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*